Business Context and Reporting Period
This Form 8-K filing by Ra Medical Systems, Inc. (RMED) reports on the Annual Meeting of Stockholders held on June 4, 2021. The registrant is incorporated in Delaware and trades on the NYSE American. The filing details the outcomes of three specific proposals submitted to shareholders.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. There are no disclosures regarding revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes and Voting Results
As of the record date (April 9, 2021), 3,255,980 shares of common stock were outstanding. At the meeting, 2,007,152 shares were present in person or by proxy. The material outcomes were:
- Director Elections: Two Class III directors, William R. Enquist, Jr. and Richard Mejia, Jr., were re-elected to serve until the 2024 annual meeting.
- Equity Plan Amendment: Shareholders approved an amendment to the 2018 Equity Incentive Plan. This amendment increases the share reserve by 270,000 shares and modifies the "evergreen" provision to remove the cap on reserved shares. Starting January 1, 2022, the reserve will automatically increase by 5% of outstanding shares annually (or a lesser amount determined by the Board).
- Accounting Firm Ratification: The appointment of Haskell & White LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2021, was ratified.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, management commentary on future operations, or specific risk factors. The primary focus is the successful ratification of the equity plan amendment, which alters the company's future share issuance mechanics.
Investor Verification Checklist
- Verify the exact terms of the amended 2018 Equity Incentive Plan in Exhibit 99.1 to understand the new share reserve mechanics.
- Confirm the impact of the 5% annual "evergreen" provision on potential future dilution.
- Review the definitive proxy statement filed on April 26, 2021, for the full summary of the Plan's material terms referenced in this filing.